Delving into the Latest Updates on AC02(Nanjing Han Xin) with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

Target-

Action-

Mechanism-

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication

Spasms, Infantile

Inactive Indication-

Originator Organization

Nanjing Han Xin Pharmaceutical Technology Co., Ltd.

Active Organization

Nanjing Han Xin Pharmaceutical Technology Co., Ltd.

Amphastar Nanjing Pharmaceuticals, Inc.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的：评估注射用AC02在健康受试者中单/多次给药后的安全性和耐受性。次要目的：评估注射用AC02在健康受试者中单/多次给药后的药代动力学特征和药效动力学特征；评估注射用AC02在健康受试者中单/多次给药后的免疫原性特征；评估注射用AC02对健康受试者QTc间期的影响。

[Translation]

Primary objective: To evaluate the safety and tolerability of AC02 for injection after single/multiple administration in healthy subjects. Secondary objectives: To evaluate the pharmacokinetic and pharmacodynamic characteristics of AC02 for injection after single/multiple administration in healthy subjects; To evaluate the immunogenicity characteristics of AC02 for injection after single/multiple administration in healthy subjects; To evaluate the effect of AC02 for injection on the QTc interval in healthy subjects.

Start Date23 Dec 2024

Sponsor / Collaborator

Nanjing Han Xin Pharmaceutical Technology Co., Ltd.

[+1]

100 Clinical Results associated with AC02(Nanjing Han Xin)

Login to view more data

100 Translational Medicine associated with AC02(Nanjing Han Xin)

Login to view more data

100 Patents (Medical) associated with AC02(Nanjing Han Xin)

Login to view more data

100 Deals associated with AC02(Nanjing Han Xin)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Spasms, Infantile	Phase 1	China	Amphastar Nanjing Pharmaceuticals, Inc.	23 Dec 2024
Spasms, Infantile	Phase 1	China	Nanjing Han Xin Pharmaceutical Technology Co., Ltd.	23 Dec 2024